2.2CiteScore
26 daysTime to First Decision

International Journal of Translational Medicine, Volume 5, Issue 1

March 2025 - 12 articles

Cover Story: The FDA’s recent approval for resmetirom in the United States serves as a milestone achievement in developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a disease with a rich history of candidates failing to achieve clinical efficacy. However, with much still unknown about the molecular mechanisms of this chronic liver disorder and the long-term efficacy and safety of this groundbreaking treatment, investigators continue to pursue all avenues of therapeutics, both novel and re-purposed, to identify additional treatment strategies for MASH. Here, we discuss alternative options amid late-phase clinical trial investigation of resmetirom to hopefully contribute to the ranks of MASH therapeutics that may contribute alongside it. View this paper

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (12)

Select all

Case Report

1 Citations

3,117 Views

10 Pages

Evaluation of the Timed Up and Go Test in Patients with Knee Osteoarthritis Using Inertial Sensors

Elina Gianzina,
Christos K. Yiannakopoulos,
Georgios Kalinterakis,
Spilios Delis and
Efstathios Chronopoulos

Int. J. Transl. Med.2025, 5(1), 2;https://doi.org/10.3390/ijtm5010002

25 December 2024

Background: There has been a growing interest in using inertial sensors to explore the temporal aspects of the Timed Up and Go (TUG) test. The current study aimed to analyze the spatiotemporal parameters and phases of the TUG test in patients with kn...

Full Article

Review

1 Citations

3,677 Views

15 Pages

The Druggable Target Potential of NF-κB-Inducing Kinase (NIK) in Cancer

Yina Wang and
Liangyou Rui

Int. J. Transl. Med.2025, 5(1), 1;https://doi.org/10.3390/ijtm5010001

25 December 2024

NF-κB-inducing kinase (NIK) is primarily recognized for its role as the apical kinase that activates non-canonical NF-κB signaling and its involvement in immune system regulation. NIK is crucial for maintaining cellular health by regulati...

Full Article

of 2

Get Alerted

Add your email address to receive forthcoming issues of this journal.

Int. J. Transl. Med. - ISSN 2673-8937

Imprint

Download Flyer